

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 7630)

**POLL RESULTS OF THE ANNUAL
GENERAL MEETING HELD ON JUNE 25, 2026
AND
AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The board (the “**Board**”) of directors (the “**Director(s)**”) of IMPACT Therapeutics, Inc (the “**Company**”) is pleased to announce that the annual general meeting of the Company was held at 10:00 a.m. on Thursday, June 25, 2026 at Board Room, 27F, New Bund Times Square, 399 West Haiyang Rd., Pudong District, Shanghai, the PRC. References are made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of the annual general meeting of the Company both dated June 3, 2026. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular. The annual general meeting was held in accordance with the requirements of the Listing Rules, the Company Law of the PRC and the Articles of Association.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The poll results of the annual general meeting were as follows:

ORDINARY RESOLUTIONS		NUMBER OF VOTES (APPROXIMATE PERCENTAGE OF VOTES (%))		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the work report of the Board for the year 2025.	184,724,824 (98.956462%)	0 (0.000000%)	1,948,001 (1.043538%)
2.	To consider and approve the accountant's report for the year ended December 31, 2025.	184,724,824 (98.956462%)	0 (0.000000%)	1,948,001 (1.043538%)
3.	To consider and approve the 2025 profit distribution plan of the Company.	184,724,825 (98.956463%)	0 (0.000000%)	1,948,000 (1.043537%)
4.	To consider and approve the re-appointment of auditor of the Company for the year ending December 31, 2026 and to hold office until the conclusion of next annual general meeting of the Company and to authorise the Board to determine its remuneration.	184,724,825 (98.956463%)	0 (0.000000%)	1,948,000 (1.043537%)

SPECIAL RESOLUTIONS		NUMBER OF VOTES (APPROXIMATE PERCENTAGE OF VOTES (%))		
		FOR	AGAINST	ABSTAIN
5.	To consider and approve the proposed amendments to the Articles of Association.	184,724,825 (98.956463%)	0 (0.000000%)	1,948,000 (1.043537%)
6.	To consider and approve the resolution on the grant of a general mandate to the Board to issue Shares.	183,196,825 (98.137919%)	1,528,000 (0.818544%)	1,948,000 (1.043537%)
7.	To consider and approve the resolution on the grant of a general mandate to the Board to repurchase H Shares.	184,724,825 (98.956463%)	0 (0.000000%)	1,948,000 (1.043537%)

Note:

- (1) For details, please refer to the Circular.

As more than half of the votes were cast in favour of the above resolutions numbered 1 to 4 proposed at the annual general meeting, each of the aforesaid resolutions was duly passed as an ordinary resolution.

As majority of more than two-thirds of the votes were cast in favor of resolutions numbered 5 to 7 at the annual general meeting, each of the aforesaid resolutions were duly passed as a special resolution.

- (2) As of the date of the annual general meeting, the total number of Shares in issue was 282,461,530 H Shares, the holders of which were entitled to attend and vote on the resolutions at the annual general meeting. There were no Shares entitling the holders to attend and abstain from voting in favour of any resolutions at the annual general meeting as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on any resolutions at the annual general meeting. No Shareholder had stated his/her intention in the Circular to vote against or to abstain from voting on any resolutions at the annual general meeting. Shareholders holding a total of 186,672,825 H Shares attended and voted at the annual general meeting either in person or by proxy, representing approximately 66.087876% of the Company's total Shares in issue.
- (3) The H Share registrar of the Company, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for vote-taking at the annual general meeting.
- (4) The executive directors, Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA, non-executive directors, Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU, and independent non-executive directors, Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO attended the annual general meeting either in person or by electronic means.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

As the special resolution in relation to the proposed amendments to the Articles of Association has been duly approved by the Shareholders at the annual general meeting, the proposed amendments to the Articles of Association will come into effect on the date of approval of the relevant resolutions. The amended Articles of Association will be published on the website of the Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the website of the Company (www.impacttherapeutics.com), respectively.

By order of the Board
IMPACT Therapeutics, Inc
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, June 25, 2026

As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive directors.